Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.

Stephen C Bain Ellen BurgessPriya VartGlenn M ChertowFan Fan HouNiels JongsJohn Joseph Valentine McMurrayRicardo Correa-RotterHarpreet S BajajBergur V StefanssonRobert D TotoAnna Maria LangkildeDavid C WheelerHiddo J Lambers Heerspinknull null

Published in: Diabetes care (2021)

Dapagliflozin safely reduced kidney and cardiovascular events independent of baseline glycemic status.

Keyphrases